DOI: 10.1097/01.COT.0000324884.03466.66

,  

Issn Print: 0276-2234

Publication Date: 2008/06/10


Print

Case Closed (If There Was Still Any Doubt): High-Dose Chemotherapy & Autologous Stem-Cell Transplant As Adjuvant Therapy for Breast Cancer

Alice Goodman

    loading  Checking for direct PDF access through Ovid

Excerpt

SAN ANTONIO—High-dose chemotherapy and autologous stem cell transplant did not provide any benefit over standard-dose chemotherapy in the adjuvant setting in breast cancer, according to an expansive meta-analysis of 15 randomized controlled trials conducted around the world between 1988 and 2002. That was the conclusion of Donald Berry, PhD, Professor and Head of the Division of Quantitative Sciences and Chairman of the Department of Biostatistics at the University of Texas M. D. Anderson Cancer Center, reporting the data at the San Antonio Breast Cancer Symposium.
No matter which way the data were analyzed, this controversial, arduous modality turned out to offer false hope to women with breast cancer, he said.

Related Topics

    loading  Loading Related Articles